Brief Introduction

Founded in 2009 , Easton Biopharmaceuticals is a high-tech enterprise integrating R & D, production and sales of chemical raw materials, high-end chemical medicines and biopharmaceuticals with approximately 1,000 employees. Eason Biopharmaceuticals was listed in the SSE STAR Market in September 2020. Confronting with “Healthy China Initiative”, the company is devoted to drug research and development, focusing on major diseases such as anesthesiology & pain management, cardiovascular, oncology, children's medicines, and diabetes. It has realized the industrialization of 20 high-end chemical drugs and 14 chemical material medicines. Easton Biopharmaceuticals has 3 first generic drugs for domestic market, 4 generic drugs have passed the consistency evaluation, and a few chemical material medicines have been certified or through registration in mainstream international markets such as the European Union, Japan, and the United States, promoting innovative development of Chinese pharmaceutical manufacturing industry.

Easton Biopharmaceuticals continues to maintain high R&D investment to build core competitiveness. The R&D expense to total revenue accounted for more than 16% from 2017 to 2019, which is much higher than industry average. Easton Biopharmaceuticals has proposed a strategy that is basing on high-end generic drugs, focusing on small-molecule innovative drugs, and seeking the development of biological drugs.

The company has more than 10 innovative drugs under development, of which 2 has entered clinical trials phase I and II respectively, and many biological drugs under preclinical study. With strong product reserves, Easton Biopharmaceuticals has accelerated the pace of technological innovation and internationalization, adhering to “Self-fulfillment, serving for all, becoming the most valued and trusted pharmaceutical company for customers around the world”, Easton will be committed to be a patient oriented, clinic-needs guided company.

Company Overview

Full name Chengdu EASTON BiopharmaceuticalsCo.,Ltd.
Code 688513
Founded 2009.06.01
Listing 2020.09.02
Domicile Chengdu, China
STAR Theme Biomedicine
CSRCSector PharmaceuticalManufacturing
Has weighted voting rights structure? No



  2019 2018 2017
Earnings Per Share 1.21 1.50 0.72
R&D expenditure as a % of operating revenue 16.53% 16.18% 16.21%
Operating Revenue 947.24 768.76 476.34
Net Income 108.61 135.02 64.37

Income Statement (Unit: RMB mn)

  2019 2018 2017
Operating Revenue 947.24 768.76 476.34
Operating Costs 884.92 677.33 432.49
Operating Income 114.73 149.14 74.27
Pretax Income 115.91 148.33 74.47
Income Tax 7.30 13.31 10.10
Net Income 108.61 135.02 64.37

Balance Sheet(Unit: RMB mn)

  2019 2018 2017
Current Assets-Total 631.29 528.82 407.69
Non-current Assets-Total 355.79 260.87 184.29
Total Assets 987.08 789.69 591.98
Current Liabilities-Total 277.12 192.77 130.21
Non-current Liabilities-Total 12.52 14.73 16.49
Total Liabilities 289.64 207.50 146.70
Stockholder's Equity
Share Capital 341.43 313.16 311.66
Retained Profits 356.01 269.04 133.62
Total Owners' Equity 697.44 582.19 445.28

Cash Flow Statement (Unit: RMB mn)

  2019 2018 2017
Net Cash Flows-Operating 141.83 166.79 85.70
Net Cash Flows-Investing -87.99 -74.81 -14.11
Net Cash Flows-Financing -13.86 - -26.50

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
Wang Ying 41.90 34.89%
Min Zhou 9.50 7.91%
ChengduNanyuan Investment Partnership 6.86 5.71%
Jibai(Shanghai) Enterprise Management Consulting Co. , Ltd. 5.11 4.25%
CITIC Securities Investment Co. , Ltd. 3.70 3.08%
CITIC securities-China Merchants Bank-CITIC securities Easton Biopharmaceuticals employees participation in strategic placement asset management plan 3.01 2.51%
Beijing Rongyuan Investment Partnership 3.00 2.50%
Chengdu Zhuyuan Investment Partnership 2.19 1.82%
Yuan Mingxu 2.00 1.67%
Wang Ronghua 2.00 1.67%
30 Spe 2020

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.